Santhera Pharmaceuticals Holding AG

Santhera Pharmaceuticals Holding AG

Hohenrainstrasse 24

4133Pratteln

    • Rechtsform:

    • Aktiengesellschaft
    • Status:

    • aktiv

    • Kapitalisierung:

    • CHF 11'164'563.00
    • Gründungsjahr:

    • 2000

    • D-U-N-S® Nr.:

    • 48-098-9461

Nachfolgend sowie unter den weiteren Menüpunkten finden Sie alle wichtigen Informationen über die Santhera Pharmaceuticals Holding AG. Neben öffentlichen Daten finden Sie auch Informationen zu Zahlungserfahrungen, Geschichte, Firmenstruktur und Finanzen sowie zur Vernetzung der verantwortlichen Personen.

Schauen Sie genauer hin!

screen_bonitaetsauskunft

Bonität & Betreibungen

Mehr zur Zahlungsfähigkeit erfahren und Überraschungen vermeiden.

Kostenlose Firmen-Überwachung

Wir informieren Sie über wichtige Änderungen.

Handelsregister

    • Handelsregistereintrag:

    • 02.02.2000

    • Rechtlicher Sitz:

    • 4133 Pratteln

    • HR-Nummer:

    • CH-270.3.012.442-0

    • UID:

    • CHE-105.388.338

    • HR-Amt:

    • Kanton Basel-Landschaft

    • Revisionsstelle:

    • Ernst & Young AG

Management & Mitarbeiter

Finanzielles

    • Bonitätsauskunft:

    • Informieren Sie sich hier über die Kreditwürdigkeit, Bonität und Zahlungsfähigkeit der Firma Santhera Pharmaceuticals Holding AG.

      Zur Santhera Pharmaceuticals Holding AG konnten wir das Zahlungsverhalten zu insgesamt 47 Rechnungen auswerten.

      Bonität prüfen
    • Betreibungsauszug:

    • Es liegt uns noch kein Betreibungsauszug vor.

      Sie möchten wissen, ob zur Firma Santhera Pharmaceuticals Holding AG Betreibungen am Register verzeichnet sind? Gerne holen wir für Sie beim zuständigen Betreibungsamt einen aktuellen Auszug ein, den Sie hier bestellen können.

      Betreibungsauskunft bestellen
    • Risiko-Analyse:

    • Sie mögen alle Infos auf einen Blick? In der Risiko-Analyse zur Santhera Pharmaceuticals Holding AG haben Sie Bonität, Score, reelle Zahlungserfahrungen und einen Betreibungsauszug in einem Bericht.

      Risiko-Analyse einsehen
    • Bonitäts-Zertifikat:

    • Firmen, welche über mehrere Jahre eine hohe Bonität ausweisen, können diese mit einer Urkunde bestätigen lassen.

      Bonitäts-Zertifikat

Firmennamen & Kontakt

    • Aktueller Firmenname:

    • Santhera Pharmaceuticals Holding AG

    • Aktuelle Adresse:

    • Hohenrainstrasse 24

      4133 Pratteln

    • Ehemalige Namen:

    • Santhera Pharmaceuticals AG (bis 10.05.2006)

      MyoContract AG (bis 20.09.2004)

      MyoContract Pharmaceutical Research AG (bis 22.07.2002)

Tätigkeit

    • Firmenzweck:

    • Erwerb, Halten, dauernde Verwaltung, Veräusserung und Finanzierung von Beteiligungen. Die Gesellschaft kann für andere Gesellschaften des Konzerns Sicherheiten gewähren und Garantieverpflichtungen übernehmen. Sie kann auch Grundstücke und Immaterialgüterrechte erwerben, verwalten verwerten und verkaufen sowie andere Gesellschaften finanzieren.

    • Branche(n):

    • Investmentgesellschaften

      Finanzholdinggesellschaften

    • NOGA 2008:

    • 649901, 642001

Verbindungen

    • Tochtergesellschaften:

    • Im Ausland

News

Santhera Announces Financial Results for the First Half-Year 2019

03.09.2019

Pratteln, Switzerland, September 3, 2019 – Santhera Pharmaceuticals (SIX: SANN) reports first halfyear
results as of June 30, 2019, and provides an update on its pipeline and strategic focus.
Thomas Meier, PhD, Chief Executive Officer of Santhera, said: “Following a series of transactions which
strategically reshaped the direction of the Company, we are well positioned to advance our long-term
growth strategy of focusing on medicines to treat neuromuscular and pulmonary diseases. For 2019, we
are on track to achieve our strategic objectives, having filed for conditional marketing authorization of
Puldysa® (idebenone) in Europe for the preservation of respiratory function in Duchenne muscular
dystrophy (DMD) patients. We expect an opinion from the EMA’s Committee for Medicinal Products for
Human Use (CHMP) mid-2020. Our goal is to help all DMD patients, irrespective of causative mutations,
disease stage or age. We were therefore very pleased about the recent publication by ReveraGen of
positive Phase IIa-extension study results with vamorolone in the journal Neurology. These data together
with previous publications provide proof-of-concept that vamorolone can improve gross muscle function
outcomes in young patients with DMD and indicate a better tolerability profile than standard
corticosteroids.”
“During the period, we announced an exclusive agreement with Chiesi Group to out-license Raxone® for
the treatment of Leber’s hereditary optic neuropathy (LHON) for a total consideration of up to EUR 93
million with an upfront payment of EUR 44 million. In monetizing this commercial product, we have
strengthened our financial position to focus on upcoming regulatory milestones and commercialization
activities for our neuromuscular and pulmonary product candidates, which are core to our long-term
growth strategy.”
Financial highlights:
? 1H-2019 sales on track with CHF 18.3 million, an increase of 14% compared to 1H-2018
? Operating expenses of CHF 38.2 million (1H-2018: CHF 39.9 million)
? Operating result of CHF –22.4 million (1H-2018: CHF –26.3 million) leading to a net result of
CHF –26.9 million (1H-2018: CHF –27.4 million)
? Cash and cash equivalents of CHF 43.7 million (August 31, 2019)
? Full-year sales guidance of CHF 25-27 million
First half-year overview:
Regulatory momentum for Puldysa in DMD
In June, the European Medicines Agency (EMA) validated Santhera’s application for conditional
marketing authorization (CMA) for Puldysa (idebenone) in the treatment of respiratory dysfunction in
patients with Duchenne muscular dystrophy (DMD) who are not using glucocorticoids. The review
Santhera Announces Financial Results for the First Half-Year 2019
September 3, 2019 / Page 2 of 5
process by the EMA’s CHMP has begun and the Company expects an opinion by the CHMP around mid-
2020. In addition, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) renewed its
positive scientific opinion for idebenone for patients with DMD in respiratory function decline who are
not taking glucocorticoids, under the Early Access to Medicines Scheme (EAMS).
Long-term data with Puldysa
In February, Santhera announced the results of its SYROS study, which investigated long-term efficacy
with idebenone in slowing respiratory function loss in patients with DMD. The study demonstrated that
long-term treatment with idebenone consistently contributed to the preservation of respiratory function
for up to 6 years in a real-world setting. This long-term data further supports the potential for idebenone
to positively modify the course of respiratory function decline and delay the time to clinically relevant
milestones.
Strong Raxone performance underscores Santhera’s commercial expertise
Net sales of Raxone in Europe amounted to CHF 18.3 million (1H-2018: CHF 16.0 million) which
corresponds to a 14% increase year-on-year, in line with the previous full-year product sales guidance.
In May, the Company announced that it had entered into an exclusive license agreement with Chiesi
Group for Raxone for the treatment of LHON, for a total consideration of up to EUR 93 million. With the
closing at the end of July, Santhera has now transferred all rights to Chiesi Group for the development,
commercialization and distribution of Raxone for the treatment of LHON and any other potential
ophthalmological indications for all territories worldwide except the US and Canada. After the closing
and for an interim period, Santhera will provide support services to Chiesi Group to enable a seamless
handover of the business and will continue to commercialize Raxone for LHON in France.
Positive study data with vamorolone published– pivotal study enrolling
Last month, positive data from 6-month Phase IIa-extension study (VBP15-003) with vamorolone in DMD
were published by ReveraGen in Neurology [1]. The data demonstrated dose-related improvement of
gross muscle function in patients with DMD treated with vamorolone. Vamorolone was reported to be
safe and well tolerated up to the highest dose tested (6.0 mg/kg/day). Biomarker data indicated reduced
occurrence of side effects typical for traditional corticosteroid drugs. Based on these data, vamorolone
has potential to replace standard corticosteroids currently used in patients with DMD.
ReveraGen is presently enrolling the Phase IIb VISION-DMD study [2] (VBP15-004; clinicaltrials.gov:
NCT03439670), designed as a pivotal efficacy and safety trial. The study is expected to be fully enrolled
by the end of 2019. Accordingly, the 6-month randomized placebo-controlled treatment period would
end by mid-2020, followed by data analysis. NDA submission could be towards year end 2020.
Collaboration to advance gene therapy research for rare neuromuscular disease
Santhera initiated a collaboration with the Biozentrum of the University of Basel to advance gene therapy
research for the treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2 MD or MDC1A).
The preclinical research collaboration builds on previous work with omigapil, which was recently studied
in a Phase I clinical trial and could act complementary. The program is supported by public funding for
innovation in Switzerland through a grant from Innosuisse – the Suisse Innovation Agency.
Santhera Announces Financial Results for the First Half-Year 2019
September 3, 2019 / Page 3 of 5
Continued investment in clinical development
Santhera is running several late-stage clinical trials, among them SIDEROS, the largest ever conducted
study in patients with DMD. The SIDEROS study is 84% recruited and positive outcome of the study will
form the basis for NDA submission for patients with DMD irrespective of glucocorticoid status, currently
expected in 2H-2021. In addition, the preparation of the MAA for Puldysa, remaining post-approval
clinical work for Raxone in LHON and increased clinical development work with POL6014 entailed slightly
higher development expenses of CHF 19.3 million (+2% year-on-year). Overall, operating expenses
showed a small decline (–4%) driven by lower expenses for commercial activities (–10%).
Liquidity base allows for the continuation of the strategy as planned
In April, Santhera raised CHF 7.1 million by the placement of 500,000 shares. As of the end of June 2019,
Santhera had cash and cash equivalents of CHF 12.7 million (December 31, 2018: CHF 22.0 million).
Together with the net proceeds from the initial payment from Chiesi Group following closing of the
licensing transaction, liquid funds amounted to CHF 43.7 million (August 31, 2019), allowing the
Company to proceed with its clinical trial program and regulatory filings as planned.
Outlook and Guidance
Based on the performance in the first half-year of 2019, the Company expects to achieve annual net sales
with Raxone in the currently approved indication LHON of CHF 25-27 million in 2019, taking into account
that Chiesi Group has taken over commercial sales for Raxone from August in all European countries
except France. The operational priorities for 2019 are the preparation of European market entry with
Puldysa in DMD in 2020, completing enrollment into the DMD SIDEROS trial to support the planned USsubmission
of Puldysa in DMD, and advancing the other clinical stage candidates in the pipeline,
particularly vamorolone and POL6014.

Weitere News anzeigen

Nachbarschaft

Firmenprüfzeichen

Zeigen Sie Ihren Website-Besuchern, dass die Firma Santhera Pharmaceuticals Holding AG im Handelsregister eingetragen ist; bauen Sie dazu einfach diesen Code auf Ihrer Webseite ein.

Eintrag editieren

  • Eintrag editieren

  • Haben Sie Ergänzungen oder Korrekturen zum monetas-Eintrag der Santhera Pharmaceuticals Holding AG?

    Eintrag editieren
Anzeige
Anzeige